Suggested remit - To appraise the clinical and cost effectiveness of LentiGlobin within its marketing authorisation for treating transfusion-dependant beta-thalassaemia
Following on from information provided to NICE by the company in August 2021, the appraisal of Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 968
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Stakeholders
- Companies sponsors
- bluebird bio (betibeglogene autotemcel)
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- Sickle Cell Society
- UK Thalassaemia Society
- Professional groups
- British Society for Haematology
- Royal College of Pathologists
- Royal College of Physicians
- Comparator companies
- Chiesi (deferiprone)
- Novartis Pharmaceuticals (desferrioxamine, deferasirox)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- Cell and Gene Therapy Catapult
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 December 2022 | Discontinued. Following on from information provided to NICE by the company in August 2021, the appraisal of Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 02 December 2021 | Note added to the project documents |
| 18 August 2021 | Note added to the project documents |
| 18 August 2021 | Suspended. This appraisal has been suspended while Bluebird Bio explores how to give patients in Europe access to its gene therapies in light of its forthcoming operational changes. A further update will be provided by late autumn. |
| 11 August 2021 | Note added to the project documents |
| 14 July 2021 | Committee meeting: 2 |
| 11 February 2021 - 04 March 2021 | Draft guidance |
| 13 January 2021 | Committee meeting: 1 |
| 03 September 2020 | In progress. In Appraisal |
| 05 May 2020 | Schedule affected by COVID-19. Topic update: this appraisal has not been defined as therapeutically critical. The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide an update when this information is available. |
| 06 April 2020 | Note added to the project documents |
| 01 August 2019 | Invitation to participate |
| 01 August 2019 | In progress. Invitation to participate |
| 14 June 2019 - 12 July 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 15 April 2019 | Note added to the project documents |
| 16 May 2018 (10:00) | Scoping workshop (London) |
| 21 March 2018 - 20 April 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual